These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12839719)

  • 1. Adverse reactions following annual ivermectin treatment of onchocerciasis in Nigeria.
    Oyibo WA; Fagbenro-Beyioku AF
    Int J Infect Dis; 2003 Jun; 7(2):156-9. PubMed ID: 12839719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The community-based treatment of onchocerciasis in Shao, Kwara State, Nigeria.
    Oyibo WA; Fagenro-Beyioku AF
    Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):496-503. PubMed ID: 12693582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community response to repeated annual ivermectin treatment of onchocerciasis in Nigeria.
    Oyibo WA; Fagbenro-Beyioku AF
    Parasitol Res; 2002 Jul; 88(7):704-7. PubMed ID: 12107465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse reactions from community directed treatment with ivermectin (CDTI) for onchocerciasis and loiasis in Ondo State, Nigeria.
    Otubanjo OA; Adeoye GO; Ibidapo CA; Akinsanya B; Okeke P; Atalabi T; Adejai ET; Braide E
    Rev Biol Trop; 2008 Dec; 56(4):1635-43. PubMed ID: 19419072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintaining compliance to ivermectin in communities in two West African countries.
    Whitworth JA; Alexander ND; Seed P; Thomas W; Abiose A; Jones BR
    Health Policy Plan; 1996 Sep; 11(3):299-307. PubMed ID: 10160375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting the attrition of community-directed distributors of ivermectin, in an onchocerciasis-control programme in the Imo and Abia states of south-eastern Nigeria.
    Emukah EC; Enyinnaya U; Olaniran NS; Akpan EA; Hopkins DR; Miri ES; Amazigo U; Okoronkwo C; Stanley A; Rakers L; Richards FO; Katabarwa MN
    Ann Trop Med Parasitol; 2008 Jan; 102(1):45-51. PubMed ID: 18186977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of community compliance with annual ivermectin treatment of onchocerciasis in Patigi, Nigeria.
    Oyibo WA; Fagbenro-Beyiku AF
    East Afr Med J; 1998 Apr; 75(4):237-42. PubMed ID: 9745842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of health education on community participation in rapid assessment of onchocerciasis prior to distribution of ivermectin.
    Shu EN; Nwadike KI; Onwujekwe EO; Ugwu OC; Okonkwo PO
    East Afr Med J; 1999 Jun; 76(6):320-3. PubMed ID: 10750518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting adverse event reporting during mass ivermectin treatment for onchocerciasis.
    Chijioke CP
    Acta Trop; 2000 Sep; 76(2):169-73. PubMed ID: 10936576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria.
    Brieger WR; Okeibunor JC; Abiose AO; Wanji S; Elhassan E; Ndyomugyenyi R; Amazigo UV
    Parasit Vectors; 2011 Jul; 4():152. PubMed ID: 21794139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onchocerciasis control in Nigeria: will households be able to afford community-directed treatment with ivermectin?
    Onwujekwe O; Shu E; Onwuameze O; Ndum C; Okonkwo P
    Acta Trop; 2001 Dec; 80(3):277-81. PubMed ID: 11700186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with coverage in community-directed treatment with ivermectin for onchocerciasis control in Oyo State, Nigeria.
    Brieger WR; Otusanya SA; Oke GA; Oshiname FO; Adeniyi JD
    Trop Med Int Health; 2002 Jan; 7(1):11-8. PubMed ID: 11851950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community-directed health (CDH) workers enhance the performance and sustainability of CDH programmes: experience from ivermectin distribution in Uganda.
    Katabarwa MN; Richards FO
    Ann Trop Med Parasitol; 2001 Apr; 95(3):275-86. PubMed ID: 11339887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community-perceived benefits of ivermectin treatment in northeastern Nigeria.
    Akogun OB; Akogun MK; Audu Z
    Soc Sci Med; 2000 May; 50(10):1451-6. PubMed ID: 10741580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.
    Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Kamgno J; Chippaux JP; Boussinesq M
    Lancet; 1997 Jul; 350(9070):18-22. PubMed ID: 9217715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse reactions to the ivermectin treatment of onchocerciasis patients: does infection with the human immunodeficiency virus play a role?
    Kipp W; Bamhuhiiga J; Rubaale T; Kabagambe G
    Ann Trop Med Parasitol; 2005 Jun; 99(4):395-402. PubMed ID: 15949187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onchocerciasis in Anambra State, Southeast Nigeria: clinical and psychological aspects and sustainability of community directed treatment with ivermectin (CDTI).
    Mbanefo EC; Eneanya CI; Nwaorgu OC; Oguoma VM; Otiji MO; Ogolo BA
    Postgrad Med J; 2010 Oct; 86(1020):573-7. PubMed ID: 20971709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in south-eastern Nigeria.
    Anosike JC; Dozie IN; Ameh GI; Ukaga CN; Nwoke BE; Nzechukwu CT; Udujih OS; Nwosu DC
    Ann Trop Med Parasitol; 2007 Oct; 101(7):593-600. PubMed ID: 17877878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of compliance with community-directed treatment with ivermectin for onchocerciasis control in Kabo area, southwestern Ethiopia.
    Endale A; Erko B; Weldegebreal F; Legesse M
    Parasit Vectors; 2015 Feb; 8():99. PubMed ID: 25890151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences.
    Onwujekwe O; Chima R; Shu E; Okonkwo P
    Health Policy; 2002 Oct; 62(1):31-51. PubMed ID: 12151133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.